Progress in HIV-1 vaccine development - 27/06/14

Doi : 10.1016/j.jaci.2014.04.025

Barton F. Haynes, MD ^a,^b,^c,^⁎ , M. Anthony Moody, MD ^a,^d, Munir Alam, PhD ^a,^b, Mattia Bonsignori, MD ^a,^b, Laurent Verkoczy, PhD ^a,^e, Guido Ferrari, MD ^a,^f, Feng Gao, MD ^a,^b, Georgia D. Tomaras, PhD ^a,^c,^f, Hua-Xin Liao, MD, PhD ^a,^b, Garnett Kelsoe, DSc ^a,^c
^a Duke Human Vaccine Institute, Durham, NC
^b Department of Medicine, Duke University School of Medicine, Durham, NC
^c Department of Immunology, Duke University School of Medicine, Durham, NC
^d Department of Pediatrics, Duke University School of Medicine, Durham, NC
^e Department of Pathology, Duke University School of Medicine, Durham, NC
^f Department of Surgery, Duke University School of Medicine, Durham, NC

^∗Corresponding author: Barton F. Haynes, MD, Duke Human Vaccine Institute, Duke University Medical Center, 2 Genome Court, 4090 MSRBII Bldg, Durham, NC 27710.

Abstract

The past 2 years have seen a number of basic and translational science advances in the quest for development of an effective HIV-1 vaccine. These advances include discovery of new envelope targets of potentially protective antibodies, demonstration that CD8⁺ T cells can control HIV-1 infection, development of immunogens to overcome HIV-1 T-cell epitope diversity, identification of correlates of transmission risk in an HIV-1 efficacy trial, and mapping of the coevolution of HIV-1 founder envelope mutants in infected subjects with broad neutralizing antibodies, thereby defining broad neutralizing antibody developmental pathways. Despite these advances, a promising HIV-1 vaccine efficacy trial published in 2013 did not prevent infection, and the HIV-1 vaccine field is still years away from deployment of an effective vaccine. This review summarizes what some of the scientific advances have been, what roadblocks still remain, and what the most promising approaches are for progress in design of successful HIV-1 vaccine candidates.

Le texte complet de cet article est disponible en PDF.

Key words : HIV-1, vaccine, T cells, B cells, broadly neutralizing antibodies

Abbreviations used : ADCC, BCR, bnAb, Env, gp, HC, HCDR3, KYNU, SIV, UCA

Plan

New Events in HIV-1 vaccine research

The way forward

	Series editors: Donald Y. M. Leung, MD, PhD, and Dennis K. Ledford, MD
	Supported by grants from the National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, UM1-AI100645), and the Bill & Melinda Gates Foundation (OPP1033098).